

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
17 April 2025 (17.04.2025)



(10) International Publication Number
WO 2025/080786 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) A61K 31/519 (2006.01)
A61P 35/00 (2006.01)

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:

PCT/US2024/050702

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:

10 October 2024 (10.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/543,598 11 October 2023 (11.10.2023) US

(71) Applicant: **BLUEPRINT MEDICINES CORPO-
RATION** [US/US]; 45 Sidney Street, Cambridge, MA
02139 (US).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:


- with international search report (Art. 21(3))

(72) Inventors: **DE PAOLIS, Omar**; c/o Blueprint Medicines
Corporation, 45 Sidney Street, Cambridge, MA 02139 (US).
HEINRICH, Brian; c/o Blueprint Medicines Corporation,
45 Sidney Street, Cambridge, MA 02139 (US). **KAUFF-
MAN, Goss Stryker**; c/o Blueprint Medicines Corporation,
45 Sidney Street, Cambridge, MA 02139 (US). **KINKE-
MA, Caitlin N.**; c/o Blueprint Medicines Corporation, 45
Sidney Street, Cambridge, MA 02139 (US). **LI, Hui**; c/o
Blueprint Medicines Corporation, 45 Sidney Street, Cam-
bridge, MA 02139 (US). **STUTZ, Alfred**; c/o Dottikon Ex-
clusive Synthesis AG, Hembrunnstrasse 17, 5605 Dottikon
(CH). **OHMER, Harald**; c/o Dottikon Exclusive Synthesis
AG, Hembrunnstrasse 17, 5605 Dottikon (CH).

(74) Agent: **ZHANG, Xin** et al.; McCarter & English, LLP, 265
Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) Title: SALT AND SOLID FORMS OF AN EGFR INHIBITOR



Compound (I)

(57) Abstract: Freebase crystalline Form D and Form E of Compound (I) represented by the following formula are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions associated with wild-type EGFR inhibitions using the same, and method for making free-base crystalline Form D and E of Compound (I) thereof is also disclosed.



WO 2025/080786 A1